```html

Zollinger‑Ellison Gastrin Excess (Zollinger‑Ellison Syndrome)

What is Zollinger‑Ellison gastrin excess?

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing neuroendocrine tumors—called gastrinomas—form in the pancreas or the duodenum. These tumors secrete excessive amounts of gastrin, a hormone that normally stimulates the stomach lining to release acid. The surplus gastrin drives **hyper‑secretion of gastric acid**, which can damage the stomach and duodenal lining, lead to severe peptic ulcers, and cause a cascade of gastrointestinal symptoms.

While the condition itself is uncommon (≈ 1–3 cases per million people per year), it is clinically important because the ulcers it produces are often refractory to standard ulcer therapy and the underlying tumors may be malignant.

Common Causes

Gastrin excess in ZES is most often due to a gastrinoma, but several other situations can mimic or trigger high gastrin levels. The table below lists the main contributors:

• Gastrinoma (primary cause) – usually located in the duodenum (≈ 70 %) or pancreas.
• Multiple endocrine neoplasia type 1 (MEN‑1) – a hereditary syndrome that includes gastrinomas in ~20‑30 % of patients.
• Multiple endocrine neoplasia type 4 (MEN‑4) – a rarer genetic syndrome with similar tumor profile.
• Familial isolated gastrinoma – autosomal‑dominant inheritance without other MEN features.
• Non‑functioning neuroendocrine tumors that acquire gastrin‑secreting ability.
• Chronic atrophic gastritis – loss of parietal cells leads to compensatory gastrin rise (though not true ZES).
• Helicobacter pylori infection – stimulates gastrin release; usually transient.
• Proton‑pump inhibitor (PPI) over‑use – long‑term acid suppression removes negative feedback on gastrin.
• Renal failure – impaired clearance of gastrin can cause modest elevations.
• Autoimmune gastritis – similar mechanism to atrophic gastritis.

Associated Symptoms

Because the hallmark of ZES is massive acid output, patients often experience a combination of the following:

• Recurrent or persistent peptic ulcers—often multiple and located beyond the duodenum (e.g., jejunal ulcers).
• Severe upper‑abdominal or epigastric pain that may worsen after meals.
• Heartburn or acid reflux that is refractory to over‑the‑counter antacids.
• Diarrhea or steatorrhea (fatty stools) caused by acid inactivation of pancreatic enzymes.
• Nausea and vomiting, sometimes with blood (hematemesis).
• Unexplained weight loss.
• Signs of anemia such as fatigue, pallor, or shortness of breath (due to chronic GI bleeding).
• In rare cases, gastrointestinal bleeding leading to melena (black, tarry stools).

When to See a Doctor

Early medical evaluation can prevent complications and improve outcomes. Seek care promptly if you notice:

• Recurrent stomach or duodenal ulcers that do not heal after 8 weeks of standard therapy.
• Severe, constant abdominal pain, especially after meals.
• Frequent diarrhea, unexplained weight loss, or oily stools.
• Vomiting blood or passing black, tarry stools.
• Persistent heartburn despite daily use of a proton‑pump inhibitor.
• Family history of MEN‑1, MEN‑4, or gastrin‑producing tumors.

Diagnosis

Diagnosing Zollinger‑Ellison syndrome involves a stepwise approach that combines laboratory testing, imaging, and, when necessary, tissue sampling.

1. Biochemical Confirmation

• Fasting serum gastrin level – a level > 1,000 pg/mL (or > 10‑times the upper limit) in the presence of acidic gastric pH strongly suggests ZES.
• Secretin stimulation test – paradoxical rise in gastrin after intravenous secretin is highly specific for gastrinoma.
• Gastric pH measurement – a pH < 2 after fasting confirms hyper‑acidic environment.

2. Imaging to Locate the Tumor

• Endoscopic ultrasound (EUS) – excellent for small pancreatic lesions.
• Multiphasic contrast‑enhanced CT or MRI – helps identify duodenal or pancreatic gastrinomas and assess for metastasis (particularly to the liver or lymph nodes).
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – detects neuroendocrine tumors that express somatostatin receptors, often the most sensitive modality.

3. Endoscopic Evaluation

Upper gastrointestinal endoscopy (EGD) is performed to visualize ulcers, obtain biopsies to rule out malignancy, and sometimes to place a feeding tube if severe malabsorption is present.

4. Genetic Testing

If a hereditary syndrome is suspected (e.g., MEN‑1), testing for mutations in the MEN1 gene (or CDKN1B for MEN‑4) is recommended for the patient and possibly for first‑degree relatives.

Treatment Options

Therapy aims to control acid hyper‑secretion, remove or shrink the gastrinoma, and monitor for recurrence. Management is usually multidisciplinary, involving gastroenterologists, endocrine surgeons, and oncologists.

Medical Management

• High‑dose proton‑pump inhibitors (PPIs) – omeprazole 60–120 mg/day, esomeprazole 40–80 mg/day, or equivalent. These drugs are the cornerstone for controlling acid output and allowing ulcer healing.
• H2‑receptor antagonists (e.g., famotidine) may be added for breakthrough symptoms.
• Antacids for occasional rapid relief.
• Somatostatin analogues (octreotide or lanreotide) – inhibit gastrin release and can shrink tumor size, especially in metastatic disease.
• Targeted therapies (e.g., everolimus, sunitinib) – used for advanced neuroendocrine tumors when surgery is not feasible.
• Chemotherapy (e.g., streptozocin‑based regimens) – reserved for high‑grade or rapidly progressive tumors.

Surgical Options

• Enucleation – removal of a small, well‑localized gastrinoma, typically when < 2 cm and no evident spread.
• Pancreaticoduodenectomy (Whipple procedure) – indicated for larger pancreatic tumors or those involving the duodenum.
• Distal pancreatectomy – for tumors located in the body or tail of the pancreas.
• Liver metastasectomy – considered when hepatic lesions are limited and resectable.
• Debulking surgery – reduces tumor burden to improve symptom control when complete resection isn’t possible.

Home & Lifestyle Measures

• Take PPIs exactly as prescribed; never skip doses.
• Avoid NSAIDs, aspirin, and other ulcer‑promoting drugs unless directed by a physician.
• Eat small, frequent meals; avoid large, fatty meals that can exacerbate acid secretion.
• Stay hydrated; diarrhea can lead to electrolyte loss.
• Limit alcohol and quit smoking, both of which impair ulcer healing.

Prevention Tips

Because most gastrinomas arise spontaneously, true prevention is limited. However, risk reduction strategies focus on early detection and minimizing secondary triggers that can worsen acid output.

• Family screening: If you have a known MEN‑1 or MEN‑4 mutation, undergo regular biochemical (fasting gastrin) and imaging surveillance as advised by genetics specialists.
• Limit chronic PPI use: Use the lowest effective dose and discuss periodic drug holidays with your doctor to avoid iatrogenic gastrin elevation.
• Eradicate Helicobacter pylori when present—testing and treatment can reduce gastrin stimulation.
• Monitor kidney function if you have chronic renal disease, as reduced clearance can modestly raise gastrin.
• Healthy diet and weight management – reduces the need for high‑dose acid‑suppressing medications.

Emergency Warning Signs

These symptoms require immediate medical attention (call 911 or go to the nearest emergency department):

• Vomiting bright red blood or material that looks like coffee grounds.
• Black, tarry stools (melena) indicating upper GI bleeding.
• Severe, sudden abdominal pain that does not improve with usual ulcer medication.
• Profound weakness, dizziness, or fainting (possible sign of significant blood loss or anemia).
• High fever (> 101 °F / 38.3 °C) combined with abdominal pain—possible perforated ulcer.

---

**References** (accessed 2024):

• Mayo Clinic. “Zollinger‑Ellison syndrome.” mayoclinic.org
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison syndrome.” niddk.nih.gov
• American College of Gastroenterology. “Management of Gastric Acid Hypersecretion.” gi.org
• World Health Organization. “Neuroendocrine Tumors – Classification & Guidelines.” 2023.
• Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison syndrome) – Diagnosis and Treatment.” clevelandclinic.org

```